Compare Gen Digital Inc. Common Stock (GEN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gen Digital Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Gen Digital Inc. Common Stock trades at $23.7 (market cap $14.24B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Gen Digital Inc. Common Stock is the larger of the two by market cap, and Gen Digital Inc. Common Stock pays a 2.1% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gen Digital Inc. Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GEN | SYRE | |
|---|---|---|
Market Cap | $14.24B | $7.52B |
Volume | 6,202,699 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $31.41 | $108.92 |
52-Week Low | $17.89 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $21.89B | $6.52B |
Dividend Yield | 2.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GEN Digital Inc. (GEN) trades at $23.81, up 1.97% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 13.92, net income margin of 20.73%, and robust cash flow from operations of $1.22B in 2025. Recent news highlights include a takeover bid for GoDaddy and participation in investor conferences, reflecting strategic moves in the cybersecurity and digital services sector.
The outlook is mixed: analyst consensus targets $25.50 with a balanced buy/hold split, but technical indicators suggest near-term pressure. Key risks include high debt levels and integration challenges from acquisitions. Earnings growth and market expansion into AI services present opportunities, though volatility may persist amid competitive and macroeconomic headwinds.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gen Digital Inc. Common Stock
Gen Digital provides cybersecurity, online privacy, identity protection, and financial wellness services. Its consumer brands include Norton, Avast, LifeLock, and MoneyLion.
Read more on GEN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
